Telix Pharmaceuticals Ltd. (TLX)
8.96
+0.10
(+1.19%)
USD |
NASDAQ |
Nov 18, 16:00
8.955
0.00 (0.00%)
After-Hours: 20:00
Telix Pharmaceuticals Price to Book Value : 25.33 for Nov. 18, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 25.33 |
| November 17, 2026 | 25.03 |
| November 16, 2026 | 25.22 |
| November 13, 2026 | 26.09 |
| November 12, 2026 | 26.46 |
| November 11, 2026 | 27.49 |
| November 10, 2026 | 26.71 |
| November 09, 2026 | 27.96 |
| November 06, 2026 | 27.22 |
| November 05, 2026 | 26.63 |
| November 04, 2026 | 27.34 |
| November 03, 2026 | 25.53 |
| November 02, 2026 | 25.58 |
| October 30, 2026 | 25.73 |
| October 29, 2026 | 26.88 |
| October 28, 2026 | 26.18 |
| October 27, 2026 | 25.53 |
| October 26, 2026 | 25.41 |
| October 23, 2026 | 25.87 |
| October 22, 2026 | 26.97 |
| October 21, 2026 | 28.35 |
| October 20, 2026 | 31.55 |
| October 19, 2026 | 30.36 |
| October 16, 2026 | 30.22 |
| October 15, 2026 | 29.88 |
| Date | Value |
|---|---|
| October 14, 2026 | 30.11 |
| October 13, 2026 | 30.87 |
| October 12, 2026 | 31.92 |
| October 09, 2026 | 31.69 |
| October 08, 2026 | 31.12 |
| October 07, 2026 | 31.44 |
| October 06, 2026 | 30.47 |
| October 05, 2026 | 30.76 |
| October 02, 2026 | 29.82 |
| October 01, 2026 | 30.30 |
| September 30, 2026 | 31.01 |
| September 29, 2026 | 32.06 |
| September 28, 2026 | 32.85 |
| September 25, 2026 | 32.37 |
| September 24, 2026 | 31.97 |
| September 23, 2026 | 31.86 |
| September 22, 2026 | 33.78 |
| September 21, 2026 | 31.97 |
| September 18, 2026 | 35.59 |
| September 17, 2026 | 35.35 |
| September 16, 2026 | 33.44 |
| September 15, 2026 | 36.27 |
| September 14, 2026 | 33.30 |
| September 11, 2026 | 31.92 |
| September 10, 2026 | 33.64 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Mesoblast Ltd. | 1.990 |
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. | -- |
| Propanc Biopharma, Inc. | 0.2448 |
Price to Book Value Related Metrics
| PE Ratio | 95.83 |
| PS Ratio | 3.490 |
| Price | 8.96 |
| Earnings Yield | 1.04% |
| Market Cap | 3.044B |
| Normalized PE Ratio | 164.10 |